These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36033919)

  • 1. Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas.
    Cho NS; Hagiwara A; Eldred BSC; Raymond C; Wang C; Sanvito F; Lai A; Nghiemphu P; Salamon N; Steelman L; Hassan I; Cloughesy TF; Ellingson BM
    Neurooncol Adv; 2022; 4(1):vdac124. PubMed ID: 36033919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
    Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
    J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology.
    Foltyn M; Nieto Taborda KN; Neuberger U; Brugnara G; Reinhardt A; Stichel D; Heiland S; Herold-Mende C; Unterberg A; Debus J; von Deimling A; Wick W; Bendszus M; Kickingereder P
    Neurooncol Adv; 2020; 2(1):vdaa004. PubMed ID: 32642675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
    Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
    Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients.
    Jafari-Khouzani K; Loebel F; Bogner W; Rapalino O; Gonzalez GR; Gerstner E; Chi AS; Batchelor TT; Rosen BR; Unkelbach J; Shih HA; Cahill DP; Andronesi OC
    Neuro Oncol; 2016 Nov; 18(11):1569-1578. PubMed ID: 27382115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment.
    Huang RY; Young RJ; Ellingson BM; Veeraraghavan H; Wang W; Tixier F; Um H; Nawaz R; Luks T; Kim J; Gerstner ER; Schiff D; Peters KB; Mellinghoff IK; Chang SM; Cloughesy TF; Wen PY
    Neuro Oncol; 2020 Dec; 22(12):1822-1830. PubMed ID: 32328652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting Genotype and Survival in Glioma Using Standard Clinical MR Imaging Apparent Diffusion Coefficient Images: A Pilot Study from The Cancer Genome Atlas.
    Wu CC; Jain R; Radmanesh A; Poisson LM; Guo WY; Zagzag D; Snuderl M; Placantonakis DG; Golfinos J; Chi AS
    AJNR Am J Neuroradiol; 2018 Oct; 39(10):1814-1820. PubMed ID: 30190259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-nuclear sodium, diffusion, and perfusion MRI in human gliomas.
    Cho NS; Sanvito F; Thakuria S; Wang C; Hagiwara A; Nagaraj R; Oshima S; Lopez Kolkovsky AL; Lu J; Raymond C; Liau LM; Everson RG; Patel KS; Kim W; Yang I; Bergsneider M; Nghiemphu PL; Lai A; Nathanson DA; Cloughesy TF; Ellingson BM
    J Neurooncol; 2023 Jun; 163(2):417-427. PubMed ID: 37294422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telomerase reverse transcriptase promoter mutation and histologic grade in IDH wild-type histological lower-grade gliomas: The value of perfusion-weighted image, diffusion-weighted image, and
    Ikeda S; Sakata A; Fushimi Y; Okuchi S; Arakawa Y; Makino Y; Mineharu Y; Nakajima S; Hinoda T; Yoshida K; Miyamoto S; Nakamoto Y
    Eur J Radiol; 2023 Feb; 159():110658. PubMed ID: 36571926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas.
    Yang X; Lin Y; Xing Z; She D; Su Y; Cao D
    Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging.
    Lee S; Choi SH; Ryoo I; Yoon TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
    J Neurooncol; 2015 Jan; 121(1):141-50. PubMed ID: 25205290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient.
    Maynard J; Okuchi S; Wastling S; Busaidi AA; Almossawi O; Mbatha W; Brandner S; Jaunmuktane Z; Koc AM; Mancini L; Jäger R; Thust S
    Radiology; 2020 Jul; 296(1):111-121. PubMed ID: 32315266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apparent diffusion coefficient for molecular subtyping of non-gadolinium-enhancing WHO grade II/III glioma: volumetric segmentation versus two-dimensional region of interest analysis.
    Thust SC; Hassanein S; Bisdas S; Rees JH; Hyare H; Maynard JA; Brandner S; Tur C; Jäger HR; Yousry TA; Mancini L
    Eur Radiol; 2018 Sep; 28(9):3779-3788. PubMed ID: 29572636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multi-reader comparison of normal-appearing white matter normalization techniques for perfusion and diffusion MRI in brain tumors.
    Cho NS; Hagiwara A; Sanvito F; Ellingson BM
    Neuroradiology; 2023 Mar; 65(3):559-568. PubMed ID: 36301349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regional and Volumetric Parameters for Diffusion-Weighted WHO Grade II and III Glioma Genotyping: A Method Comparison.
    Thust SC; Maynard JA; Benenati M; Wastling SJ; Mancini L; Jaunmuktane Z; Brandner S; Jäger HR
    AJNR Am J Neuroradiol; 2021 Mar; 42(3):441-447. PubMed ID: 33414227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study.
    Verburg N; Koopman T; Yaqub MM; Hoekstra OS; Lammertsma AA; Barkhof F; Pouwels PJW; Reijneveld JC; Heimans JJ; Rozemuller AJM; Bruynzeel AME; Lagerwaard F; Vandertop WP; Boellaard R; Wesseling P; de Witt Hamer PC
    Neuro Oncol; 2020 Mar; 22(3):412-422. PubMed ID: 31550353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
    Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
    Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ventricle contact is associated with lower survival and increased peritumoral perfusion in glioblastoma.
    van Dijken BRJ; Jan van Laar P; Li C; Yan JL; Boonzaier NR; Price SJ; ; van der Hoorn A
    J Neurosurg; 2018 Oct; 131(3):717-723. PubMed ID: 30485234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Frontline Ivosidenib on Volumetric Growth Patterns in Isocitrate Dehydrogenase-mutant Astrocytic and Oligodendroglial Tumors.
    Kamson DO; Puri S; Sang Y; Shi MJ; Blair L; Blakeley JO; Laterra J
    Clin Cancer Res; 2023 Dec; 29(23):4863-4869. PubMed ID: 37382607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic susceptibility contrast-MRI parameters, ADC values, and the T2-FLAIR mismatch sign are useful to differentiate between H3-mutant and H3-wild-type high-grade midline glioma.
    Kurokawa R; Kurokawa M; Baba A; Ota Y; Kim J; Capizzano A; Srinivasan A; Moritani T
    Eur Radiol; 2022 Jun; 32(6):3672-3682. PubMed ID: 35022811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.